Breaking News

'Academia is dying' amid postdoc flight, newborn sequencing surprise, & 'Boddities' is back

June 6, 2023
Reporter, Morning Rounds Writer
Good morning. Jonathan Wosen continues his inquiry into the exodus of life scientists from academia, Megan Molteni reports on unexpected results from newborn sequencing, and Theresa Gaffney brings back the STAT video series "Boddities" to explore season allergies. Gesundheit.

education

'Academia is dying': Life scientists flee postdocs in numbers reflecting inequities

STAT23_Postdoc_Final

Thumy Phan for STAT

For decades, the route life scientists traveled to a faculty job in academia ran first through a Ph.D. program followed by postdoctoral research. But as more graduates skip postdocs and leave academia for lucrative industry positions, a clearer picture is emerging of who's going and who's staying behind. Those who've started started families or have big loans, or are Black or female, plan to pursue postdoc positions at lower rates than their peers, according to a STAT analysis that includes previously unreported National Science Foundation data.

"I'm deeply concerned that academia is dying," Sofie Kleppner, associate dean of postdoctoral affairs at Stanford, told STAT's Jonathan Wosen. "If the academic world is not warm and welcoming and diverse, it is going to die." When the pay is so low a Harvard lab shares a calendar of where free food is available, people put down their pipettes for protest signs — or just leave, Jonathan reports. Read more.


cancer

Who's behind AstraZeneca's wins, a CAR-T milestone, and a difference of opinion at the FDA

ASCO, the big cancer conference in Chicago, concludes today. Highlights from STAT's Adam Feuerstein, Angus Chen, and Matthew Herper:

  • Susan Galbraith, who heads AstraZeneca's oncology research and development, was watching from the audience Sunday when "extraordinary" survival rates were presented for Tagrisso, which cut the death rate in half for certain lung cancer patients. Matt profiles the woman behind AstraZeneca's cancer winning streak.
  • In another milestone for CAR-T therapy, Gilead's Yescarta prolonged the lives of patients with large B-cell lymphoma by 27% compared to standard treatment in a long-running randomized clinical trial, researchers reported yesterday. Adam has more
  • At a STAT event Sunday night, Richard Pazdur, director of the FDA's Oncology Center of Excellence, took issue with his boss. FDA Commissioner Robert Califf would like to do away with expert panels voting on whether drugs should win approval, but Pazdur says, "I think we need to vote." Angus has more here.

genomics

Newborn sequencing uncovers risk for parents

Newborn DNA-sequencing isn't just for babies, a new study tells us. Instead, the program screening for hidden genetic disorders turned up unexpected mutations in disease-associated genes, prompting members of 17 affected families to get further testing. In three cases, mothers learned they carried a gene that drastically elevated their risks of certain cancers — and they chose to undergo prophylactic surgeries to reduce those risks. 

"There are ethicists who say a child should not be used as a genetic canary in a coal mine," said medical geneticist Robert Green, who leads the BabySeq study behind the new research. "Look at these mothers. We arguably saved their lives." When the trial was launched in 2013, Green and his colleagues debated how much genetic information to give parents about their new child, deciding to disclose only genetic variants implicated in childhood-onset conditions. STAT's Megan Molteni explains how and why their thinking shifted. 



Closer Look

'Boddities' is back: What's up with seasonal allergies?

STAT

Longtime STAT fans may recall when Morning Rounds pioneer (now senior news editor) Megan Thielking also appeared in videos exploring the body's oddities in a series called, naturally, "Boddities." Now STAT reporter and podcast producer Theresa Gaffney (above) is back on the beat, this time asking why we get seasonal allergies.

Scientists don't fully understand what's causing the sneezing, sniffling, and itching that plague us after winter's end, but one theory says it's probably an immune response to toxins in the natural environment that pollen also happens to trigger. Theresa explains the cascade that begins with IgE antibodies battling the pollen before calling in reinforcements in the form of mast cells. Don't despair: There are ideas of how to fight back. Watch here.


health inequity

Sickle cell disease plays a role in maternal outcomes

As drugs for sickle cell disease are now available and gene therapies are on the horizon, it may be surprising that little is known about how the disease figures into another serious outcome affecting more Black people than others: severe maternal morbidity. That umbrella term includes sepsis, heart failure, and sickle cell crises (some requiring blood transfusions) during hospital stays surrounding childbirth. Black patients are more likely to have these adverse outcomes, attributed to higher rates of preeclampsia, chronic hypertension, and pre-pregnancy diabetes.

Researchers writing in JAMA Pediatrics say sickle cell disease has been studied in maternal mortality, preeclampsia, stillbirth, and preterm delivery, but overlooked as contributing to severe maternal morbidity. Their analysis of 8.5 million deliveries concludes sickle cell disease accounted for 9% of the Black-white disparity in adverse outcomes requiring transfusion and 14% that didn't. "It is imperative to develop new interventions for SCD that consider pregnancy outcomes," they say.


health care 

Gaps narrow in LGBT health coverage, not access

It wasn't that long ago that compared to other adults, LGBT people faced significantly higher hurdles to obtaining health insurance and as a consequence, health care. In 2015, two events changed the coverage landscape: passage of the Affordable Care Act and a Supreme Court ruling affirming marriage equality. A new study in Health Affairs tracking differences between LGBT adults and other adults — with or without partners — from 2013 through 2019 found that while disparities in coverage began to narrow when the ACA went into effect, disparities in access to health care persist.

From 2017 through 2019, LGBT people were equally likely to have a usual source of care, but they were more likely to say they had trouble paying medical bills. That meant they were more likely than non-LGBT peers to have delayed or gone without health care because of its cost. The gap has thinned since 2013, the researchers note.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • FDA removes neurologist with financial ties to Eisai and Biogen from Alzheimer's advisory panel, STAT
  • Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna data, Reuters
  • Carbon Health is already using AI to write patient records, STAT
  • To ease cancer drug shortage, FDA will allow imports from China, NBCNews 

  • Ted Love, BIO's first Black board chair, aims to rehab biotech's image in Washington, STAT

Thanks for reading! More tomorrow,


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2023, All Rights Reserved.

No comments